• Citer

RAD51-based homologous recombination deficiency is associated with treatment response and survival in early breast cancer

par Llop-Guevara, Alba;Pellegrino, Benedetta;Pimentel, Isabel;Villacampa, Guillermo;Solinas, Cinzia ;Torres-Esquius, Sara;Campanini, Nicoletta;Simonetti, Sara;Tommasi, Chiara O.;Serra, Olga;Corianò, Matilde;Boggiani, Daniela;Michiara, Maria;Minari, Roberta;Bortesi, Beatrice;Rapacchi, Elena;Dieci, Maria Vittoria;Lambertini, Matteo Md Phd M.;Zoppoli, Gabriele;Schirone, Alessio;Casarini, Chiara;Cretella, Elisabetta;Cortesi, Laura;Silini, Enrico Maria;Saura, Cristina;Willard-Gallo, Karen ;Boisson, Anaïs;Musolino, Antonino;Serra, Violeta;Balmaña, Judith;Cruz, Cristina
Référence NPJ breast cancer, 12, 1, 58
Publication Publié, 2026-12

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

Advances in breast cancer (BC) therapy are limited by the absence of well-established biomarkers for DNA-damage targeted treatments. We evaluated the predictive and prognostic value of homologous recombination repair (HRR) deficiency (HRD) by RAD51 nuclear foci and stromal tumour-infiltrating lymphocytes (TILs) in early-stage BC patients with suspected germline susceptibility. Among 291 patients, HRD by RAD51 was found in 78.4% of tumours, and 69.8% had low TILs (<30%). In 178 patients treated with neoadjuvant chemotherapy, pathologic complete response (pCR) was higher in those with HRD vs HRR-proficient (HRP) tumours (52.3% vs 36.4%); RAD51 remained independently associated with pCR (p = 0.03). Overall survival (OS) favoured HRD, with 5-year OS of 89.2% vs 82.8% in HRP (p = 0.009), with stronger evidence in triple-negative TILs-low disease (p = 0.005). These findings support RAD51-based HRD assessment as a predictive and prognostic biomarker that may guide treatment decisions in early-stage BC.